New York, USA – July 27, 2021 – DDA platform, the division of Creative Bioarray, whose mission focuses on developing cutting-edge products and high quality services that can satisfy the needs in the field of biotechnology, pharmaceuticals and diagnostics etc. Recently, DDA platform launches a wide range of genotoxicity testing services (non-GLP) for the application in drug discovery research.
Genotoxicity testing of new chemical entities is an integral part of the drug development process and is a regulatory requirement before new drug approval. By determining genotoxicity in the early stages of drug discovery rather than during regulatory evaluation, the likelihood of late failure can be reduced. If there is any positive reaction in the in vitro study, a follow-up in vivo study is usually required for the same endpoint. The genotoxicity test provided by Creative Bioarray includes the following:
Bacterial Reverse Mutation Test (Ames Test): In the bacterial reverse mutation test, Salmonella typhimurium and E. coli strains that require amino acids are used to detect mutation points. These mutation points may involve substitution, deletion or addition of one or several base pairs. It detects mutations, restores the mutations present in the tested strain and restores the function of the bacteria to synthesize essential amino acids. Bacterial reverse mutation test is fast, cheap and easy to perform, and is usually used as a preliminary screening test for genotoxicity or mutagenicity.
In Vitro Mammalian Chromosome Aberration Test: Chromosome aberration test aims to identify the factors that cause chromosome structural aberrations by using cultured mammalian somatic cells (peripheral blood lymphocytes, Chinese hamster ovary cell line (CHO)). After the cell culture is exposed to the test substance, the cells are treated with metaphase blocker, harvested and stained. Then analyze the metaphase cells under a microscope for chromosomal aberrations.
In Vitro Mammalian Cell Micronucleus Test (MNvit): The micronucleus test detects micronuclei in the cytoplasm of interphase cells. Micronuclei may come from acentromeric chromosomal segments (those lacking centromeres) or entire chromosomes that cannot migrate to the poles in the late stage of cell division. This method identifies the cleavage and embryonic activity of cells that undergo cell division during or after exposure to the test substance.
In Vitro Comet Test: Also known as single-cell gel electrophoresis (SCEG) test, is a sensitive method for rapid detection of single-cell DNA damage, including double-strand breaks, single-strand breaks and alkali-labile sites. Comet test detects the migration of DNA in the agarose gel after electrophoresis, resulting in a “head” of intact DNA and a “tail” of fragmented DNA. The percentage of DNA in the tail of the comet is used as a measure of DNA damage.
“Our genotoxicity test complies with ICH S2 recommendations and provides objective and consistent data.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “Creative Bioarray can help you understand the toxicity of compounds using a set of different techniques. We can help determine which compounds have the best safety to enter the clinic with the most advanced technology and automation.”
About Creative Bioarray
Founded in 2005, Creative Bioarray is dedicated to offering customers with innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house experts supported, Creative Bioarray has already countenanced research all around the world.